Multidimensional Molecular Biomarkers In Advanced Heart Failure – The MyLeukoMAPTM Rationale
Abstract
In this review, we develop the hypothesis that accurate longitudinal clinical phenotype assessment and leukocyte phenome/transcriptome modeling allow developing MMB-predictors of “progression/death on OMM in HFrEF” and a better comparative survival benefit prediction than by clinical predictors alone.
Keywords
heart failure; prognostication; survival benefit; genomc biomarker
Full Text:
Subscribers OnlyDOI: http://dx.doi.org/10.18103/imr.v0i6.127
Refbacks
- There are currently no refbacks.